A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this is a Phase 2 trial comparing blinatumomab alone to blinatumomab combined with nivolumab for first-relapse B-ALL, what is currently known about the safety of adding nivolumab to blinatumomab, and what additional risks might come with the combination that wouldn't exist with blinatumomab alone?
2. 2The trial is measuring whether patients achieve MRD-negative remission — a very deep level of remission with no detectable leukemia — so how does my child's or my current disease burden affect the likelihood of reaching that goal, and how does that compare to what standard reinduction chemotherapy might offer?
3. 3I noticed the trial has separate groups, including one specifically for patients with Down Syndrome — is there a particular group that would apply to my situation, and how does that affect what treatment I'd actually receive and what the study is trying to learn?
4. 4Since this trial is actively recruiting and still in Phase 2, the long-term outcome data isn't fully established yet — given where we are in my treatment, would my doctor recommend trying standard salvage therapy first, or is there a reason to consider this trial at this specific point in my relapse?
5. 5What would the treatment schedule and monitoring visits actually look like for this trial in terms of how often I'd need to come in, how long treatment lasts, and whether this could be managed given my current living situation and support system?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.